Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib, S-1, or capecitabine maintenance therapy after radical surgery for biliary tract tumors
ChiCTR1800015601Phase 4Recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Apr 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of Rivoceranib, tegafur and capecitabine in biliary adenocarcinoma, gallbladder adenocarcinoma and cholangiocarcinoma (CCA) (4 arms), sponsored by Hengrui Therapeutics. Primary endpoint: Disease-free survival. Started Apr 2018; status: recruiting.
02
Drugs
Rivoceranibtegafurcapecitabine
03
Conditions
biliary adenocarcinomagallbladder adenocarcinomacholangiocarcinoma (CCA)
Beyond the preview
Go deeper on ChiCTR1800015601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015601.